author-photo

Paul L. Baron

Medical University of South Carolina

53

Papers

1242

Citations

Citation Trend

Filter By

Papers (44) Sort By

Journal Conference Others

Abstract PS4-04: Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Pegloprastide-Based Ratiometric Fluorescence Imaging Detects Intraoperative Positive Margins in Real-Time

2021
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PD9-01: 5-year outcomes in the NBRST trial: Preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Abstract P6-08-28: Comprehensive germline multigene panel testing changes clinical care for patients with breast cancer

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P2-16-21: Novel use of a precision medicine tool in the neoadjuvant therapy setting

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Comprehensive germline multigene panel testing changes clinical care for patients with breast cancer: Untapped clinical utility and PARP inhibitor trial eligibility.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Pathological complete response in basal subtype tumors to predict improved distant metastasis free survival in the NBRST trial.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

2017 Annals of Surgical Oncology
Show All
- Source
- Cite
- Save
Citations (29)
Abstract P4-14-29: One-third of HER2 positive patients have 80-gene luminal subtype that is resistant to chemo-trastuzumab but sensitive to chemo-trastuzumab-pertuzumab: Critical implications for the adjuvant setting from the NBRST phase 4 neoadjuvant study:

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P1-14-05: Three distinct HER2 subtypes identified by BluePrint 80-gene functional subtyping predict treatment-specific response in the prospective neo-adjuvant NBRST registry

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)